How Efficacious Must a COVID-19 Coronavirus Vaccine be to Prevent or Stop an Epidemic by Itself
Preprint
- 30 May 2020
- preprint
- Published by Cold Spring Harbor Laboratory in medRxiv
Abstract
Background: Given the continuing coronavirus disease 2019 (COVID-19) pandemic and much of the U.S. implementing social distancing due to the lack of alternatives, there has been a push to develop a vaccine to eliminate the need for social distancing.Methods: In 2020, we developed a computational model of the U.S. simulating the spread of COVID-19 coronavirus and vaccination.Results: Simulation experiments revealed that when vaccine efficacy exceeded 70%, coverage exceeded 60%, and vaccination occurred on day 1, the attack rate dropped to 22% with daily cases not exceeding 3.2 million (reproductive rate, R0, 2.5). When R0 was 3.5, the attack rate dropped to 41% with daily cases not exceeding 14.4 million. Increasing coverage to 75% when vaccination occurred by day 90 resulted in 5% attack rate and daily cases not exceeding 258,029when R0 was 2.5 and a 26% attack rate and maximum daily cases of 22.6 million when R0 was 3.5. When vaccination did not occur until day 180, coverage (i.e., those vaccinated plus those otherwise immune) had to reach 100%. A vaccine with an efficacy between 40% and 70% could still obviate the need for other measures under certain circumstances such as much higher, and in some cases, potentially unachievable, vaccination coverages.Conclusion: Our study found that to either prevent or largely extinguish an epidemic without any other measures (e.g., social distancing), the vaccine has to have an efficacy of at least 70%.Keywords
All Related Versions
- Published version: , 59 (4), 493.
This publication has 38 references indexed in Scilit:
- Estimating the cost-effectiveness of a national program to eliminate disparities in influenza vaccination rates among elderly minority groupsVaccine, 2011
- The cost-effectiveness of vaccinating pregnant women against seasonal influenza in England and WalesVaccine, 2010
- Cost-effectiveness of dual influenza and pneumococcal vaccination in 50-year-oldsVaccine, 2010
- Constructing target product profiles (TPPs) to help vaccines overcome post-approval obstaclesVaccine, 2010
- Staphylococcus aureus vaccine for orthopedic patients: An economic model and analysisVaccine, 2010
- Health Outcomes and Costs of Community Mitigation Strategies for an Influenza Pandemic in the United StatesClinical Infectious Diseases, 2010
- Infection control measures for norovirus: a systematic review of outbreaks in semi-enclosed settingsJournal of Hospital Infection, 2010
- Cost-effectiveness of treating influenzalike illness with oseltamivir in the United StatesAmerican Journal of Health-System Pharmacy, 2009
- Cost-effectiveness of live attenuated influenza vaccine versus inactivated influenza vaccine among children aged 24–59 months in the United StatesVaccine, 2008
- Toward Consistency in Cost-Utility AnalysesMedical Care, 1998